CN105832752A - Pharmaceutical composition for clinical nursing of upper respiratory infection - Google Patents
Pharmaceutical composition for clinical nursing of upper respiratory infection Download PDFInfo
- Publication number
- CN105832752A CN105832752A CN201610218810.3A CN201610218810A CN105832752A CN 105832752 A CN105832752 A CN 105832752A CN 201610218810 A CN201610218810 A CN 201610218810A CN 105832752 A CN105832752 A CN 105832752A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- acid
- upper respiratory
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
Abstract
The invention discloses a pharmaceutical composition for clinical nursing of upper respiratory infection. The pharmaceutical composition mainly consists of the following components in parts by weight: 0.1-0.6 parts of syringin, 0.2-0.5 parts of calanolide E, 0.1-0.4 parts of aurantio-obtusin, 0.5-0.8 parts of protocatechuic acid, 0.6-0.8 parts of sialbin, 0.2-0.6 parts of ursolic acid, 0.1-0.5 parts of bergenin, 0.1-0.7 parts of butyl gallate, 0.2-0.3parts of robinin, 0.4-1.2 parts of columbin, 0.3-0.5 parts of thymol, 0.2-0.4 parts of glutathione, 0.6-0.8 parts of phytosterol, 0.9-1.5 parts of vitamin V and 0.8-2.3 parts of compound amino acid. The pharmaceutical composition disclosed by the invention is capable of resisting bacteria, diminishing inflammation, resisting viruses, clearing away heat and toxic materials, relieving exterior syndrome and relieving cough and boosting body immunity, and the pharmaceutical composition is capable of effectively improving various adverse symptoms in patients with the upper respiratory infection; and the pharmaceutical composition is significant in effect, mild in overall prescription and free from obvious side effects.
Description
Technical field
The present invention relates to Respiratory Medicine nursing practical technique field, be specifically related in a kind of clinical care breathe
The pharmaceutical composition that road infects.
Background technology
Upper respiratory tract infection great majority are caused by virus, including rhinovirus, coronavirus, adenovirus,
Influenza and parainfluenza virus, respiratory syncytial virus, echovirus, Coxsackie virus etc..Separately have 20%～
The upper sense of 30% is caused by antibacterial, and antibacterial infects and is often secondary to after virus infects, with Hemolytic streptococcus for
Common, it is secondly hemophilus influenza, streptococcus pneumoniae, staphylococcus etc., is occasionally gram-negative bacteria.
These disease four seasons, any age all can fall ill, by containing the virulent spittle, droplet, or the apparatus through polluting
Propagate.Often when Abwehrkraft des Koepers reduces, as caught cold, fatigue, the situation such as drench with rain, former existed or
The virus invaded by the external world, or/and antibacterial, mushrooms out breeding, causes infecting.This disease prognosis bona, has certainly
Sex-limited ,-as 5-7 days recovery from illness.Chang Jifa bronchitis, pneumonia, nasal sinusitis, a few peoples can complicated with acute
Myocarditis, nephritis, rheumatic fever etc..
Cause the extraneous factor of this disease, the various reasons causing whole body or respiratory tract local defense function to reduce,
As suffered from cold, drenching with rain, abrupt change of climate, fatigue etc. can make former that be present in upper respiratory tract or invade from the external world
The virus or the antibacterial that enter breed rapidly, thus induce primary disease.Old germling is weak, immunologic hypofunction or suffer from slow
The patient susceptible of property respiratory tract disease.
Existing medicine is mainly antiviral drug, and curative effect is inconspicuous, poor prognosis, the most also can give
Patient brings side effect, increases patient suffering.
Summary of the invention
Present invention solves the technical problem that and be to provide-the pharmaceutical composition of kind of clinical care upper respiratory tract infection, effect
Fruit is notable, is effectively improved patients symptomatic, alleviates patient suffering.
The technical scheme is that, the pharmaceutical composition of a kind of clinical care upper respiratory tract infection, by weight
Component meter, mainly consists of the following composition: Syringa oblata Lindl. phenolic glycoside 0.1-0.6 part, poon element E 0.2-0.5
Part, aurantio-obtusin 0.1-0.4 part, protocatechuic acid 0.5-0.8 part, Sinapine glucosinalbate. 0.6-0.8 part, Bears
Fruit acid 0.2-0.6 part, Bergeninum 0.1-0.5 part, butyl gallate 0.1-0.7 part, acaciin
0.2-0.3 part, fibralactone 0.4-1.2 part, thymol 0.3-0.5 part, glutathion 0.2-0.4
Part, plant sterol 0.6-0.8 part, vitamin C 0.9-1.5 part, aminoacids complex 0.8-2.3 part.
Optimum ratio is: Syringa oblata Lindl. phenolic glycoside 0.35 part, poon element E 0.35 part, aurantio-obtusin 0.25 part,
Protocatechuic acid 0.65 part, Sinapine glucosinalbate. 0.7 part, ursolic acid 0.4 part, Bergeninum 0.3 part, Galla Turcica (Galla Helepensis)
Acid butyl ester 0.4 part, acaciin 0.25 part, fibralactone 0.8 part, thymol 0.4 part, glutathion
0.3 part, plant sterol 0.7 part, vitamin C 1.2 parts, aminoacids complex 1.55 parts.
The extraction preparation method of described Sinapine glucosinalbate. is: take the sodium chloride that Semen Sinapis Albae mass fraction is 3-6% molten
Immersion is steeped 20-30 minute, and taking-up is dried, and is ground into coarse powder, is placed in 160-220 DEG C of process 2-5 in baking box
Minute, take out, cooling, be again placed in baking box 150-180 DEG C and process 4-6 minute, take out, cooling,
By the pure water reflux, extract, twice of 6 times amount, 1.3 hours for the first time, 0.5 hour for the second time, merge back into
Flow liquid, filters, is centrifuged 8-10 minute with the rotating speed of centrifuge 800-1200r/min, takes supernatant, concentrates
Crystallization, obtains Sinapine glucosinalbate..
The extraction preparation method of described fibralactone is: takes Caulis Fibraureae and is ground into coarse powder, by 5 times amount mass concentrations
It is the alcohol reflux twice of 90%, 1.5 hours for the first time, 1.0 hours for the second time, merges back into flow liquid,
Filter, reclaim ethanol and be concentrated into every lml medical material Han 1.5g, stand crystallization, leaching crystal；Crystal
Add the ethanol that mass concentration is 90% (in terms of crystal weight) of l8-20 times amount, stirring and dissolving, heating
Reflux 4O minute, filter, filtrate recycling ethanol, stand 10 hours, filtering for crystallizing, drying under reduced pressure, powder
It is broken into fine powder, i.e. obtains fibralactone.
Further, described aminoacids complex is by Radix Asparagi aminoacid, glutamic acid, alanine, proline
The mixture of composition.
The preparation method of the pharmaceutical composition of described a kind of clinical care upper respiratory tract infection is:
(1) get the raw materials ready: weigh Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, former catechu by described proportioning
Acid, Sinapine glucosinalbate., ursolic acid, Bergeninum, butyl gallate, acaciin, fibralactone, in hundred
Fragrant phenol, glutathion, plant sterol, vitamin C, aminoacids complex；
(2) by Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, protocatechuic acid, Sinapine glucosinalbate., Folium Vaccinii vitis-idaeae
Acid, Bergeninum, acaciin, thymol, glutathion, plant sterol, vitamin C, compound ammonia
Base acid is ground into the nano powder of 200-500 nanometer, mixing, adds butyl gallate and fibralactone,
I.e. obtain described pharmaceutical composition.
Further, described compositions is prepared as corresponding oral formulations according to pharmacy conventional manner technique.
Further, described oral formulations includes: tablet, granule, capsule.
The invention has the beneficial effects as follows: the pharmaceutical composition of the present invention can antibacterial, antiinflammatory, antiviral, clearly
Thermal detoxification, cough-relieving of inducing sweat, improves patient's resistance, is effectively improved the various bad of upper respiratory tract infection patient
Symptom, effect is notable, and integral formula is gentle, non-evident effect.
Detailed description of the invention
Embodiment 1:
The pharmaceutical composition of a kind of clinical care upper respiratory tract infection, by weight component meter, mainly by following
One-tenth is grouped into: Syringa oblata Lindl. phenolic glycoside 0.1 part, poon element E 0.2 part, aurantio-obtusin 0.1 part, former catechu
Acid 0.5 part, Sinapine glucosinalbate. 0.6 part, ursolic acid 0.2 part, Bergeninum 0.1 part, butyl gallate
0.1 part, acaciin 0.2 part, fibralactone 0.4 part, thymol 0.3 part, glutathion 0.2 part,
Plant sterol 0.6 part, vitamin C 0.9 part, aminoacids complex 0.8 part.
The extraction preparation method of described Sinapine glucosinalbate. is: take the sodium chloride solution that Semen Sinapis Albae mass fraction is 3%
Soaking 20 minutes, taking-up is dried, and is ground into coarse powder, is placed in baking box 160 DEG C and processes 2 minutes, takes out,
Cooling, is again placed in baking box 150 DEG C and processes 4 minutes, take out, cooling, return with the pure water of 6 times amount
Stream extraction twice, 1.3 hours for the first time, 0.5 hour for the second time, merges back into flow liquid, filters, with centrifugal
The rotating speed of machine 800r/min is centrifuged 8 minutes, takes supernatant, condensing crystallizing, obtains Sinapine glucosinalbate..
The extraction preparation method of described fibralactone is: carry with the alcohol reflux that 5 times amount mass concentrations are 90%
Take twice, 1.5 hours for the first time, 1.0 hours for the second time, merge back into flow liquid, filter, reclaim ethanol dense
It is reduced to every lml medical material Han 1.5g, stands crystallization, leaching crystal；Crystal adds the quality of l8 times amount
Concentration is the ethanol (in terms of crystal weight) of 90%, and stirring and dissolving is heated to reflux 4O minute, filters, filter
Liquid reclaims ethanol, stands 10 hours, filtering for crystallizing, and drying under reduced pressure is ground into fine powder, i.e. obtains in Caulis Fibraureae
Ester.
The mixing that described aminoacids complex is made up of Radix Asparagi aminoacid, glutamic acid, alanine, proline
Thing, the mass ratio between four is 3:2:1:1.
This pharmaceutical composition is prepared as tablet, and preparation method is:
(1) get the raw materials ready: weigh Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, former catechu by described proportioning
Acid, Sinapine glucosinalbate., ursolic acid, Bergeninum, butyl gallate, acaciin, fibralactone, in hundred
Fragrant phenol, glutathion, plant sterol, vitamin C, aminoacids complex；
(2) by Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, protocatechuic acid, Sinapine glucosinalbate., Folium Vaccinii vitis-idaeae
Acid, Bergeninum, acaciin, thymol, glutathion, plant sterol, vitamin C, compound ammonia
Base acid is ground into the nano powder of 200 nanometers, mixing, adds butyl gallate and fibralactone, to obtain final product
To described pharmaceutical composition, add filler, bonding disintegrating agent, granulate, tabletting, be prepared as tablet.
Embodiment 2:
The pharmaceutical composition of a kind of clinical care upper respiratory tract infection, by weight component meter, mainly by following
One-tenth is grouped into: Syringa oblata Lindl. phenolic glycoside 0.35 part, poon element E 0.35 part, aurantio-obtusin 0.25 part, former youngster
Boheic acid 0.65 part, Sinapine glucosinalbate. 0.7 part, ursolic acid 0.4 part, Bergeninum 0.3 part, gallic acid fourth
Ester 0.4 part, acaciin 0.25 part, fibralactone 0.8 part, thymol 0.4 part, glutathion 0.3
Part, plant sterol 0.7 part, vitamin C 1.2 parts, aminoacids complex 1.55 parts.
The extraction preparation method of described Sinapine glucosinalbate. is: take the sodium chloride that Semen Sinapis Albae mass fraction is 4.5% molten
Immersion is steeped 25 minutes, and taking-up is dried, and is ground into coarse powder, is placed in baking box 190 DEG C and processes 3.5 minutes, takes
Go out, cooling, be again placed in baking box 165 DEG C and process 5 minutes, take out, cooling, pure by 6 times amount
Water reflux, extract, twice, 1.3 hours for the first time, 0.5 hour for the second time, merges back into flow liquid, filters, and uses
The rotating speed of centrifuge 1000r/min is centrifuged 9 minutes, takes supernatant, condensing crystallizing, obtains Sinapine glucosinalbate..
The extraction preparation method of described fibralactone is: carry with the alcohol reflux that 5 times amount mass concentrations are 90%
Take twice, 1.5 hours for the first time, 1.0 hours for the second time, merge back into flow liquid, filter, reclaim ethanol dense
It is reduced to every lml medical material Han 1.5g, stands crystallization, leaching crystal；Crystal adds the quality of 19 times amount
Concentration is the ethanol (in terms of crystal weight) of 90%, and stirring and dissolving is heated to reflux 4O minute, filters, filter
Liquid reclaims ethanol, stands 10 hours, filtering for crystallizing, and drying under reduced pressure is ground into fine powder, i.e. obtains in Caulis Fibraureae
Ester.
The mixing that described aminoacids complex is made up of Radix Asparagi aminoacid, glutamic acid, alanine, proline
Thing, the mass ratio between four is 3:2:1:1.
This pharmaceutical composition is prepared as granule, and preparation method is:
(1) get the raw materials ready: weigh Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, former catechu by described proportioning
Acid, Sinapine glucosinalbate., ursolic acid, Bergeninum, butyl gallate, acaciin, fibralactone, in hundred
Fragrant phenol, glutathion, plant sterol, vitamin C, aminoacids complex；
(2) by Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, protocatechuic acid, Sinapine glucosinalbate., Folium Vaccinii vitis-idaeae
Acid, Bergeninum, acaciin, thymol, glutathion, plant sterol, vitamin C, compound ammonia
Base acid is ground into the nano powder of 350 nanometers, mixing, adds butyl gallate and fibralactone, to obtain final product
To described pharmaceutical composition, add filler, binding agent, correctives are prepared as granule.
Embodiment 3:
The pharmaceutical composition of a kind of clinical care upper respiratory tract infection, by weight component meter, mainly by following
One-tenth is grouped into: Syringa oblata Lindl. phenolic glycoside 0.6 part, poon element E 0.5 part, aurantio-obtusin 0.4 part, former catechu
Acid 0.8 part, Sinapine glucosinalbate. 0.8 part, ursolic acid 0.6 part, Bergeninum 0.5 part, butyl gallate
0.7 part, acaciin 0.3 part, fibralactone 1.2 parts, thymol 0.5 part, glutathion 0.4 part,
Plant sterol 0.8 part, vitamin C 1.5 parts, aminoacids complex 2.3 parts.
The extraction preparation method of described Sinapine glucosinalbate. is: take the sodium chloride solution that Semen Sinapis Albae mass fraction is 6%
Soaking 30 minutes, taking-up is dried, and is ground into coarse powder, is placed in baking box 220 DEG C and processes 5 minutes, takes out,
Cooling, is again placed in baking box 180 DEG C and processes 6 minutes, take out, cooling, return with the pure water of 6 times amount
Stream extraction twice, 1.3 hours for the first time, 0.5 hour for the second time, merges back into flow liquid, filters, with centrifugal
The rotating speed of machine 1200r/min is centrifuged 8-10 minute, takes supernatant, condensing crystallizing, obtains Sinapine glucosinalbate..
The extraction preparation method of described fibralactone is: carry with the alcohol reflux that 5 times amount mass concentrations are 90%
Take twice, 1.5 hours for the first time, 1.0 hours for the second time, merge back into flow liquid, filter, reclaim ethanol dense
It is reduced to every lml medical material Han 1.5g, stands crystallization, leaching crystal；Crystal adds the quality of 20 times amount
Concentration is the ethanol (in terms of crystal weight) of 90%, and stirring and dissolving is heated to reflux 4O minute, filters, filter
Liquid reclaims ethanol, stands 10 hours, filtering for crystallizing, and drying under reduced pressure is ground into fine powder, i.e. obtains in Caulis Fibraureae
Ester.
The mixing that described aminoacids complex is made up of Radix Asparagi aminoacid, glutamic acid, alanine, proline
Thing, the mass ratio between four is 3:2:1:1.
This pharmaceutical composition is prepared as capsule, and preparation method is:
(1) get the raw materials ready: weigh Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, former catechu by described proportioning
Acid, Sinapine glucosinalbate., ursolic acid, Bergeninum, butyl gallate, acaciin, fibralactone, in hundred
Fragrant phenol, glutathion, plant sterol, vitamin C, aminoacids complex；
(2) by Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, protocatechuic acid, Sinapine glucosinalbate., Folium Vaccinii vitis-idaeae
Acid, Bergeninum, acaciin, thymol, glutathion, plant sterol, vitamin C, compound ammonia
Base acid is ground into the nano powder of 500 nanometers, mixing, adds butyl gallate and fibralactone, to obtain final product
To described pharmaceutical composition, add filler, binding agent, lubricant, wetting agent, be prepared as capsule.
Model case:
1, so-and-so is revived, female, 28 years old, pharyngeal discomfort, it is dried, and cough, rhinorrhea occurs, with head
The symptom of pain heating, upon examination it is found that its submandibular lymph nodes enlargement, and throat is the most congested, is diagnosed as breathing
Road infects, and uses the tablet of the embodiment of the present invention 1 preparation to treat, oral, three times a day, every time
0.5-1g, after 1 day, throat lymphadenectasis diminishes, and after 2 days, cough alleviates, and headache alleviates, and body temperature is extensive
Multiple normal, after 4 days, all ill symptomses all disappear, on inspection for recovery from illness.Follow up a case by regular visits to after 3 months, have no multiple
Send out.
2, road so-and-so, man, 21 years old, have sore throat, hoarseness, heating, headache, limbs are aching and limp weary
Power, upon examination it is found that its submandibular lymph nodes enlargement, and throat is the most congested, is diagnosed as upper respiratory tract infection, makes
Treat with the granule of the embodiment of the present invention 2 preparation, oral, three times a day, and each 0.5-1g, 1
In the future, temperature recovery is normal, and headache alleviates, and after 2 days, has sore throat and alleviates, headache relief, limbs acid
Soft weak being also eased, after 3 days, headache disappears, and throat is without significant discomfort sense, and remaining symptom is the most complete
Disappear, on inspection for recovery from illness.
3, Lee so-and-so, female, 39 years old, early discovery oneself throat discomfort, develop into the most again dry pain of itching,
And it being attended by sneeze and nasal obstruction, loss of appetite, fever and headache, submandibular lymph nodes enlargement has tenderness sense, through inspection
Looking into its submandibular lymph nodes enlargement of discovery, throat is the most congested, in being diagnosed as upper respiratory tract infection, uses this
The capsule of bright embodiment 3 preparation is treated, oral, every day 2 times, each 0.5-1g, after 2 days,
All ill symptomses are all eased, and after 5 days, all ill symptomses all disappear, and patient feels good, warp
Check as recovery from illness.
Last it is noted that above example is only in order to illustrate technical scheme, rather than right
It limits；Although the present invention being described in detail with reference to previous embodiment, the ordinary skill of this area
Personnel are it is understood that the technical scheme described in previous embodiment still can be modified by it or right
Wherein portion of techniques feature carries out equivalent；And these amendments or replacement, do not make appropriate technical solution
Essence depart from embodiment of the present invention technical scheme spirit and scope.
Claims (6)
1. the pharmaceutical composition of a clinical care upper respiratory tract infection, it is characterised in that component meter by weight,
Mainly consist of the following composition: Syringa oblata Lindl. phenolic glycoside 0.1-0.6 part, poon element E 0.2-0.5 part, orange
Obtusin 0.1-0.4 part, protocatechuic acid 0.5-0.8 part, Sinapine glucosinalbate. 0.6-0.8 part, ursolic acid 0.2-
0.6 part, Bergeninum 0.1-0.5 part, butyl gallate 0.1-0.7 part, acaciin 0.2-0.3 part,
Fibralactone 0.4-1.2 part, thymol 0.3-0.5 part, glutathion 0.2-0.4 part, plant sterol
0.6-0.8 part, vitamin C 0.9-1.5 part, aminoacids complex 0.8-2.3 part.
The pharmaceutical composition of a kind of clinical care upper respiratory tract infection the most as claimed in claim 1, its feature
It is, it is characterised in that component meter by weight, mainly consists of the following composition: Syringa oblata Lindl. phenolic glycoside 0.35
Part, poon element E 0.35 part, aurantio-obtusin 0.25 part, protocatechuic acid 0.65 part, Sinapine glucosinalbate. 0.7
Part, ursolic acid 0.4 part, Bergeninum 0.3 part, butyl gallate 0.4 part, acaciin 0.25 part,
Fibralactone 0.8 part, thymol 0.4 part, glutathion 0.3 part, plant sterol 0.7 part, dimension are raw
Element C 1.2 parts, aminoacids complex 1.55 parts.
The pharmaceutical composition of a kind of clinical care upper respiratory tract infection the most as claimed in claim 1 or 2, its
Being characterised by, described aminoacids complex is made up of Radix Asparagi aminoacid, glutamic acid, alanine, proline
Mixture.
4. the pharmaceutical composition of a kind of clinical care upper respiratory tract infection as described in claims 1 to 3, its
Being characterised by, preparation method is:
(1) get the raw materials ready: weigh Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, former catechu by described proportioning
Acid, Sinapine glucosinalbate., ursolic acid, Bergeninum, butyl gallate, acaciin, fibralactone, in hundred
Fragrant phenol, glutathion, plant sterol, vitamin C, aminoacids complex.
(2) by Syringa oblata Lindl. phenolic glycoside, poon element E, aurantio-obtusin, protocatechuic acid, Sinapine glucosinalbate., Folium Vaccinii vitis-idaeae
Acid, Bergeninum, acaciin, thymol, glutathion, plant sterol, vitamin C, compound ammonia
Base acid is ground into the nano powder of 200-500 nanometer, mixing, adds butyl gallate and fibralactone,
I.e. obtain described pharmaceutical composition.
The preparation side of the pharmaceutical composition of a kind of clinical care upper respiratory tract infection the most as claimed in claim 4
Method, it is characterised in that described compositions is prepared as corresponding oral formulations according to pharmacy conventional manner technique.
The preparation side of the pharmaceutical composition of a kind of clinical care upper respiratory tract infection the most as claimed in claim 4
Method, it is characterised in that described oral formulations includes: tablet, granule, capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610218810.3A CN105832752A (en) | 2016-04-08 | 2016-04-08 | Pharmaceutical composition for clinical nursing of upper respiratory infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610218810.3A CN105832752A (en) | 2016-04-08 | 2016-04-08 | Pharmaceutical composition for clinical nursing of upper respiratory infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105832752A true CN105832752A (en) | 2016-08-10 |
Family
ID=56597212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610218810.3A Pending CN105832752A (en) | 2016-04-08 | 2016-04-08 | Pharmaceutical composition for clinical nursing of upper respiratory infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105832752A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021064167A1 (en) * | 2019-10-04 | 2021-04-08 | Urgo Recherche Innovation Et Developpement | Combination product for relieving the bronchi |
| CN112998133A (en) * | 2021-02-24 | 2021-06-22 | 中国科学院上海药物研究所 | Plant essential oil amino acid composition and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799544A (en) * | 2004-12-31 | 2006-07-12 | 云南白药集团股份有限公司 | Compound bergenin pills and its preparation method |
| CN1969982A (en) * | 2006-12-08 | 2007-05-30 | 李剑一 | Chinese hawthorn seed and application thereof in preparation of medicament for treating respiratory tract infection and air disinfectant |
| CN101032571A (en) * | 2006-03-06 | 2007-09-12 | 王�锋 | Chinese medicine composition, the preparing method and the quality control method thereof |
| EP1894559A1 (en) * | 2006-09-01 | 2008-03-05 | PARI Pharma GmbH | Means to solubilise steroids for inhalation |
| CN102579860A (en) * | 2011-01-17 | 2012-07-18 | 山东阿如拉药物研究开发有限公司 | Child medicament extract composition and preparation method and application thereof |
| CN103249403A (en) * | 2010-09-22 | 2013-08-14 | 克劳研究有限公司 | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| CN103251060A (en) * | 2013-04-17 | 2013-08-21 | 苟春虎 | Dust-haze prevention lung heat clearing capsule |
| US20140100283A1 (en) * | 2012-10-05 | 2014-04-10 | Atlantic Pro Nutrients, Inc. dba XYMOGEN | Method to Increase Absorption and Bioavailability of Oral Glutathione |
| CN103908674A (en) * | 2014-01-21 | 2014-07-09 | 邓学峰 | Rifamycin sodium combinatorial drug |
-
2016
- 2016-04-08 CN CN201610218810.3A patent/CN105832752A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799544A (en) * | 2004-12-31 | 2006-07-12 | 云南白药集团股份有限公司 | Compound bergenin pills and its preparation method |
| CN101032571A (en) * | 2006-03-06 | 2007-09-12 | 王�锋 | Chinese medicine composition, the preparing method and the quality control method thereof |
| EP1894559A1 (en) * | 2006-09-01 | 2008-03-05 | PARI Pharma GmbH | Means to solubilise steroids for inhalation |
| CN1969982A (en) * | 2006-12-08 | 2007-05-30 | 李剑一 | Chinese hawthorn seed and application thereof in preparation of medicament for treating respiratory tract infection and air disinfectant |
| CN103249403A (en) * | 2010-09-22 | 2013-08-14 | 克劳研究有限公司 | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| CN102579860A (en) * | 2011-01-17 | 2012-07-18 | 山东阿如拉药物研究开发有限公司 | Child medicament extract composition and preparation method and application thereof |
| US20140100283A1 (en) * | 2012-10-05 | 2014-04-10 | Atlantic Pro Nutrients, Inc. dba XYMOGEN | Method to Increase Absorption and Bioavailability of Oral Glutathione |
| CN103251060A (en) * | 2013-04-17 | 2013-08-21 | 苟春虎 | Dust-haze prevention lung heat clearing capsule |
| CN103908674A (en) * | 2014-01-21 | 2014-07-09 | 邓学峰 | Rifamycin sodium combinatorial drug |
Non-Patent Citations (3)
| Title |
|---|
| 梁安鹏等: "《药物集成1药材及药材提取物（一）》", 30 June 2008 * |
| 洪筱坤等: "中成药化学成分分析测定", 《中成药》 * |
| 陈光英等: "青梅属植物的化学成分及药理作用研究进展", 《湖南师范大学学报（自然科学版）》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021064167A1 (en) * | 2019-10-04 | 2021-04-08 | Urgo Recherche Innovation Et Developpement | Combination product for relieving the bronchi |
| FR3101539A1 (en) * | 2019-10-04 | 2021-04-09 | Urgo Recherche Innovation Et Developpement | Combination product to relieve bronchial tubes |
| CN112998133A (en) * | 2021-02-24 | 2021-06-22 | 中国科学院上海药物研究所 | Plant essential oil amino acid composition and preparation method thereof |
| CN112998133B (en) * | 2021-02-24 | 2022-08-23 | 中国科学院上海药物研究所 | Plant essential oil amino acid composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7424684B2 (en) | Chinese herbal medicine complex prescription with lung purifying and detoxifying function and its application | |
| CN100402075C (en) | Pharynx clearing tea | |
| CN102357154A (en) | Traditional Chinese medicine composition for preventing and treating avian infectious bronchitis and preparation method thereof | |
| CN105770009A (en) | Herbaceous antibacterial tea and preparation method thereof | |
| CN103405739B (en) | A kind of medicine for the treatment of children's's suppurative tonsillitis | |
| CN105832752A (en) | Pharmaceutical composition for clinical nursing of upper respiratory infection | |
| CN105343268A (en) | Oral care mouth wash containing Chinese medicinal herbs | |
| CN105641081A (en) | Traditional Chinese medicine oral liquid for treating sow endometritis | |
| CN107281263A (en) | A kind of composition and preparation method thereof, sachet and application | |
| CN106237039A (en) | A kind of antibacterial cream of rhinitis and preparation method thereof | |
| CN102657724A (en) | Traditional Chinese medicine oral liquid for preventing and treating chicken infectious bronchitis and preparation method thereof | |
| CN112569279A (en) | Novel prescription for treating coronary pneumonia and using method | |
| CN102671175B (en) | A kind of traditional Chinese medicine oral liquid for preventing and treating chicken respiratory tract disease and preparation method thereof | |
| CN104906440A (en) | Traditional Chinese medicine for acute nasopharyngitis treatment | |
| CN105148247B (en) | A kind of Chinese medicine preparation and preparation method thereof for treating cold cough | |
| CN109674854A (en) | A kind of shield pharynx treasure pill and preparation method thereof | |
| CN107213205B (en) | Medicine and food formula for specific endowment constitution of children | |
| CN102727589B (en) | Medicament for treating cough with lung heat of children | |
| CN105902910A (en) | Respiratory tract infection treating drop for pediatric nursing and preparation method thereof | |
| CN105616515A (en) | Injection for epidemic cerebrospinal meningitis | |
| CN105288202A (en) | Pharmaceutical composition for curing infantile cough | |
| CN106727848A (en) | It is a kind of to treat Chinese medicine composition of hand-foot-and-mouth disease and preparation method thereof | |
| CN103638191A (en) | Traditional Chinese medicine preparation for treating acute tonsillitis | |
| CN114209773A (en) | Medicine for treating bronchitis and preparation method thereof | |
| CN103520632B (en) | One is used for the treatment of grippal Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |